ACTELION LTD AND SUBSIDIARIESContents:CONSOLIDATED INCOME STATEMENTSCONSOLIDATED BALANCE SHEETSCONSOLIDATED STATEMENTS OF CASH FLOWSCONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITYUNAUDITED CONSOLIDATED US GAAP FINANCIAL STATEMENTS FOR MARCH 31,
5
0
0
Texte intégral
(2) ACTELION LTD AND SUBSIDIARIES CONSOLIDATED INCOME STATEMENTS. Three months ended March 31, 2009 2008 UNAUDITED As Adjusted (Note 1). (in CHF thousands, except per share amounts). Net revenue: Product sales Contract revenue. 389,423 16,190. 314,639 6,937. 405,613. 321,576. Cost of sales Research and development Selling, general and administration Amortization of acquired intangible assets. 43,025 95,848 138,831 6,278. 34,088 93,918 121,022 4,786. Total operating expense. 283,982. 253,814. Operating income. 121,631. 67,762. Total net revenue. Interest income Interest expense Amortization of debt discount and issuance costs Other financial income (expense), net. 1,491 (288) (4,470) (5,374). 4,997 (1,446) (4,278) (17,641). Income before income tax expense. 112,990. 49,394. Income tax expense. (10,847). (4,920). Net income. 102,143. 44,474. Basic net income per share Weighted-average number of common shares (in thousands). 0.87 117,897. 0.38 118,364. Diluted net income per share Weighted-average number of common shares (in thousands). 0.83 122,647. 0.36 123,357. 4,973 7,137 12,110. 5,244 8,357 13,601. (1). Includes employee stock option costs as follows: Research and development Selling, general and administration Total stock-based compensation. Note 1: Prior period comparatives have been adjusted to reflect the retrospective application of FSP APB 14-1, "Accounting for Convertible Debt Instruments that May Be Settled in Cash upon Conversion, Including Partial Cash Settlement", which was adopted with effect of January 1, 2009. Note 2: Purchase accounting associated with the thermo-stable Epoprostenol business acquisition in March 2009 is still under evaluation.. WorldReginfo - 710fec5a-7c1c-477e-b632-aef70db27f3a. Operating expenses. (1).
(3) ACTELION LTD AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS. March 31, December 31, 2009 2008 UNAUDITED As Adjusted (Note 1). (in CHF thousands, except number of shares) Assets Current assets Cash and cash equivalents Short-term deposits Derivative instruments Marketable securities Trade and other receivables, net Inventories Other current assets Pension assets Deferred tax asset, current portion. 830,396 203,504 3,870 50,000 407,186 53,159 36,076 10,420 3,252. 727,459 292,935 6,639 365,864 46,037 41,955 3,200. 1,597,863. 1,484,089. 191,044 15,302 228,818 80,031 14,485 19,614. 80,882 177,588 12,513 166,658 77,728 30,378 19,968. 2,147,157. 2,049,804. Trade and other payables Accrued expenses Deferred revenue, current portion Other current liabilities Short-term financial debt. 113,867 187,743 61,533 7,489 414,494. 83,538 255,951 61,449 7,806 458,159. Total current liabilities. 785,126. 866,903. Long-term financial debt Deferred revenue, less current portion Other non-current liabilities Pension liability Deferred tax liability. 162,216 6,256 372. 146,100 178,491 6,037 8,830 344. Total liabilities. 953,970. 1,206,705. Total current assets Long-term deposits Property, plant and equipment, net Other non-current assets Intangible assets, net Goodwill Long-term financial assets Deferred tax asset Total assets. Liabilities and shareholders' equity. Shareholders' equity Common shares (par value CHF 0.50 per share, authorized 212,861,205 and 212,861,205 shares; issued 126,341,934 and 125,015,607 shares in 2009 and 2008 respectively) Additional paid-in capital Accumulated profit Treasury shares, at cost Accumulated other comprehensive loss. 63,171 941,457 672,558 (442,816) (41,183). 62,508 701,867 570,415 (442,816) (48,875). Total shareholders' equity. 1,193,187. 843,099. Total liabilities and shareholders' equity. 2,147,157. 2,049,804. Note 1: Prior period comparatives have been adjusted to reflect the retrospective application of FSP APB 14-1, "Accounting for Convertible Debt Instruments that May Be Settled in Cash upon Conversion, Including Partial Cash Settlement", which was adopted with effect of January 1, 2009. Note 2: Purchase accounting associated with the thermo-stable Epoprostenol business acquisition in March 2009 is still under evaluation.. WorldReginfo - 710fec5a-7c1c-477e-b632-aef70db27f3a. Current liabilities.
(4) ACTELION LTD AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS. Three months ended March 31, 2009 2008 UNAUDITED As Adjusted (Note 1). (in CHF thousands). Cash flow from operating activities Net income. 102,143. 44,474. Adjustments to reconcile net income to net cash provided from operating activities: Depreciation and amortization Stock-based compensation, incl. treasury shares to members of Board of Directors Excess tax benefits from share-based payment arrangements (Gains) Losses on derivative instruments Amortization of debt discount and issuance costs Trade and other receivables Inventories Other current assets Other assets Trade and other payables Accrued expenses Deferred revenue Other liabilities Changes in other operating cash flow items. 12,798 12,110 (3,130) 5,903 4,470 (31,649) (2,306) (11,508) (2,715) 30,222 (70,879) (16,190) 1,717 (3,184). 10,137 13,601 (2,824) (3,819) 4,278 (22,006) 3,925 (12,914) (10,105) (618) (30,369) (6,662) 11,729 23,269. 27,802. 22,096. Purchase of short-term and long-term deposits Proceeds from short-term and long-term deposits Purchase of property, plant and equipment Purchase of marketable securities Settlement of derivative instruments Purchase of intangible assets Acquisition of a business. (198,504) 368,817 (22,901) (50,000) (3,457) (2,469) (57,785). (142,700) 235,615 (10,405) (2,692) -. Net cash flow provided by investing activities. 33,701. 79,818. (40) (193,800) 36,703 188,637 3,130. (35) 97,900 8,112 (106,031) 2,824. Net cash flow provided by operating activities Cash flow from investing activities. Payments on capital leases Repayment of financial debts Proceeds from bank loans Proceeds from exercise of stock options, net of expense Purchase of call option Proceeds from exercise of options related to own shares Excess tax benefits from share-based payment arrangements Net cash flow provided by financing activities Net effect of exchange rates on cash and cash equivalents. 34,630. 2,770. 6,804. (17,075). Net change in cash and cash equivalents. 102,937. Cash and cash equivalents at beginning of period. 727,459. 331,586. Cash and cash equivalents at end of period. 830,396. 419,195. Note 1: Prior period comparatives have been adjusted to reflect the retrospective application of FSP APB 14-1, "Accounting for Convertible Debt Instruments that May Be Settled in Cash upon Conversion, Including Partial Cash Settlement", which was adopted with effect of January 1, 2009. Note 2: Purchase accounting associated with the thermo-stable Epoprostenol business acquisition in March 2009 is still under evaluation.. 87,609. WorldReginfo - 710fec5a-7c1c-477e-b632-aef70db27f3a. Cash flow from financing activities.
(5) ACTELION LTD AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY. Additional (in CHF thousands, except number of shares). Common shares Shares. At January 1, 2008, As Adjusted (Note 1). 118,087,219. Amount 61,014. Other. paid-in-. Accumulated. Treasury. comprehensive. Shareholders'. capital. profit. shares. income (loss). equity. 651,743. 264,629. (230,627). (29,133). 717,626. Comprehensive income (loss) net of tax: Net income. 44,474. 44,474. Other comprehensive income: Currency translation adjustment. (31,839). Comprehensive income (loss) Excess tax benefit and underrealization from share-based payment arrangement Exercise of stock options. 12,635. 882,509. 441. Transactions in treasury shares. 2,743. 2,743. 7,671. 8,112. -. Options related to own shares. -. (106,031). Exercise of options related to own shares, net Stock-based compensation expense, net At March 31, 2008, As Adjusted (Note 1). (31,839). 118,969,728. 61,455. (106,031). -. -. 13,601. 13,601. 569,727. 309,103. (230,627). (60,972). 648,686. Comprehensive income (loss) net of tax: Net income. 261,312. 261,312. Other comprehensive income: Currency translation adjustment Not recognized components of net periodic benefit costs Unrealized gain on marketable securities. Transactions in treasury shares. 7,502. (3,362). (3,362). 7,957. Comprehensive income (loss) Excess tax benefit and underrealization from share-based payment arrangement Exercise of stock options. 7,502. 7,957 273,409. 2,105,369. 1,053. (3,867,730). 4,099. 4,099. 60,308. 61,361. 59. Options related to own shares. (212,189). (212,130). -. -. Exercise of options related to own shares, net. 18,677. 18,677. Stock-based compensation expense, net. 48,997. 48,997. At January 1, 2009, As Adjusted (Note 1). 117,207,367. 62,508. 701,867. 570,415. (442,816). (48,875). 843,099. Comprehensive income (loss) net of tax: Net income. 102,143. 102,143. Other comprehensive income: Currency translation adjustment Unrealized gain on marketable securities Comprehensive income (loss) Excess tax benefit and underrealization from share-based payment arrangement. 109,835. 1,326,327. 663. Options related to own shares Stock-based compensation expense, net At March 31, 2009. 23,585 (15,893). 118,533,694. 63,171. 2,803. 2,803. 36,040. 36,703. 188,637. 188,637. 12,110. 12,110. 941,457. 672,558. Note 1: Prior period comparatives have been adjusted to reflect the retrospective application of FSP APB 14-1, "Accounting for Convertible Debt Instruments that May Be Settled in Cash upon Conversion, Including Partial Cash Settlement", which was adopted with effect of January 1, 2009. Note 2: Purchase accounting associated with the thermo-stable Epoprostenol business acquisition in March 2009 is still under evaluation.. (442,816). (41,183). 1,193,187. WorldReginfo - 710fec5a-7c1c-477e-b632-aef70db27f3a. Exercise of stock options. 23,585 (15,893).
(6)
Documents relatifs
treasury shares to members of Board of Directors Excess tax benefits from share-based payment arrangements Deferred revenue Gains Losses on derivative instruments Amortization of
treasury shares to members of Board of Directors Excess tax benefits from share-based payment arrangements Gains Losses on derivative instruments Amortization of debt discount
treasury shares to members of Board of Directors Excess tax benefits from share-based payment arrangements Gains Losses on derivative instruments Amortization of debt discount
Adjustments to reconcile net income loss to net cash provided from operating activities: Depreciation and amortization Stock-based compensation Excess tax benefits from
Adjustments to reconcile net income loss to net cash provided from operating activities: Depreciation and amortization Stock-based compensation Excess tax benefits from
[r]
The Ageas Annual Report 2019 includes the Report of the Board of Directors of Ageas prepared in accordance with the legal and regulatory requirements applicable in Belgium pursuant
Introduction We have reviewed the accompanying consolidated statement of financial position of ageas SA/NV the “Company” and its subsidiaries the “Group” as of 30 June 2019 and
